Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 3 pages · Chinese
Earlier from Hitgen
- Report for Q3 2025
- HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
- Board of Supervisors' Verification Opinions and Publicity Explanation on List of Proposed Incentive Objects in 2025 Restricted Stock Incentive Plan
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- Advancing DEL Technology for the Research Lab: HitGen Introduces OpenDEL™ 5.0
Later from Hitgen
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases
- Announcement on Results of Shareholding Reduction by Shareholder Lhasa Economic and Technological Development Zone Huabo Medical Equipment Co., Ltd.
- HitGen Submits Commitment Letter to Science Based Targets initiative (SBTi)
- Announcement on Outward Investment
Follow Hitgen into a list and get an email when it puts out news.
Follow Hitgen